A novel therapeutic strategy of lipidated promiscuous peptide against Mycobacterium tuberculosis by eliciting Th1 and Th17 immunity of host

Regardless of the fact that potent drug-regimen is currently available, tuberculosis continues to kill 1.5 million people annually. Tuberculosis patients are not only inflicted by the trauma of disease but they also suffer from the harmful side-effects, immune suppression and drug resistance instiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Rai, Pradeep K, Chodisetti, Sathi Babu, Nadeem, Sajid, Maurya, Sudeep K, Gowthaman, Uthaman, Zeng, Weiguang, Janmeja, Ashok K, Jackson, David C, Agrewala, Javed N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823727/
https://www.ncbi.nlm.nih.gov/pubmed/27052185
http://dx.doi.org/10.1038/srep23917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823727/
https://www.ncbi.nlm.nih.gov/pubmed/27052185
http://dx.doi.org/10.1038/srep23917

Ejemplares similares